Duloxetine for the Treatment of Major Depressive Disorder
By Charles B. Nemeroff, MD, PhD, Alan F. Schatzberg, MD, David J. Goldstein, MD, PhD, Michael J. Detke, MD, PhD, Craig Mallinckrodt, PhD, Yili Lu, PhD, and Pierre V. Tran, MD
A Model to Explain the Therapeutic Effects of Serotonin Reuptake Inhibitors: The Role of 5-HT2 Receptors
By Mikael Landén, MD, PhD, and Michael E. Thase, MD
Risperidone: Review of Its Therapeutic Utility in Depression
By Joyce E. Myers, MD, and Michael E. Thase, MD
Comparing the Methods Used to Compare Antidepressants
By Michael E. Thase, MD
Optimizing Treatment Outcomes for Patients With Depression and Generalized Anxiety Disorder
By Michael E. Thase, MD, and Madhukar Trivedi, MD
Remission as the Critical Outcome of Depression Treatment
By Michael E. Thase, MD, Diane M. E. Sloan, PharmD, and Susan G. Kornstein, MD
Gender-Specific Differences in Depression and Treatment Response
By Susan G. Kornstein, MD, Diane M. E. Sloan, PharmD, and Michael E. Thase, MD